Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates Upside
· seekingalpha.com
Damora Therapeutics targets mutCALR in ET/MF with potent DMR-001 and CLARITY-101 timelines, funded into 2029. Read my analysis for more.
Damora Therapeutics ( DMRA ) is not the first company to bring a mutant calreticulin antibody into clinical development; however, in my opinion, this does not r...